SCHEMBL465026

SCHEMBL465026

O=C(O)CCCN1CCOCC1

nearest known ligand 0.74

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GLA P06280 1/20 0.74
SMN1; SMN2 Q16637 4/20 0.64
MAPK1 P28482 2/20 0.64
CYP1A2 P05177 1/20 0.64
HSD17B10 Q99714 1/20 0.55
KEAP1 Q14145 1/20 0.52
ALDH1A1 P00352 5/20 0.50
MAPT P10636 2/20 0.50
KMT2A Q03164 2/20 0.50
PAOX Q6QHF9 1/20 0.50
GAA P10253 1/20 0.50
LMNA P02545 3/20 0.49
KDM4E B2RXH2 2/20 0.49
NPC1 O15118 1/20 0.48
TP53 P04637 1/20 0.48
RAB9A P51151 1/20 0.48
HPGD P15428 1/20 0.47
DUSP3 P51452 1/20 0.47
CYP2C19 P33261 1/20 0.46
HIF1A Q16665 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Bromide SCHEMBL11739950 0.98 GLA (0.71) GLASMN1; SMN2MAPK1CYP1A2HSD17B10
Hydrochloric Acid SCHEMBL1127696 0.98 GLA (0.78) GLASMN1; SMN2MAPK1CYP1A2HSD17B10
SCHEMBL1194073 0.94 GLA (0.71) GLASMN1; SMN2MAPK1CYP1A2HSD17B10
Propionic Acid SCHEMBL5410798 0.93 GLA (0.65) GLASMN1; SMN2MAPK1CYP1A2HSD17B10
SCHEMBL30489760 0.92 GLA (0.69) GLASMN1; SMN2MAPK1CYP1A2HSD17B10
SCHEMBL1194005 0.92 GLA (0.69) GLASMN1; SMN2MAPK1CYP1A2HSD17B10
Hydrochloric Acid SCHEMBL1127992 0.92 GLA (0.75) GLASMN1; SMN2MAPK1CYP1A2HSD17B10
SCHEMBL9150763 0.92 GLA (0.69) GLASMN1; SMN2MAPK1CYP1A2HSD17B10
Hydrochloric Acid SCHEMBL30684598 0.90 GLA (0.72) GLASMN1; SMN2MAPK1CYP1A2HSD17B10
SCHEMBL10487039 0.89 GLA (0.61) GLASMN1; SMN2MAPK1CYP1A2HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 220 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240002358-A1 Optically clear, taste-masked, shelf-stable nano-emulsions containing cannabinoids CCT SCIENCES, LLC 2024-01-04 US claimed
EP-2968145-A1 MODIFIED DOCETAXEL LIPOSOME FORMULATIONS Mallinckrodt LLC (US) 2016-01-20 EP claimed
CN-105188675-A Modified docetaxel liposome formulations MALLINCKRODT LLC 2015-12-23 CN claimed
EP-2724670-B1 Detecting altered pH levels of rumens KANKFELT PEKKA (FI) 2015-06-17 EP claimed
WO-2014160392-A1 MODIFIED DOCETAXEL LIPOSOME FORMULATIONS MALLINCKRODT LLC (US) 2014-10-02 WO claimed
EP-1637141-B1 Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease TROBIO AB (SE) 2011-11-16 EP claimed
WO-2011131234-A1 SENSOR APPARATUS ADAPTED TO BE INCORPORATED IN A GARMENT WEARABLE INFORMATION TECHNOLOGIES, S.L. (WEARTECH) (ES) 2011-10-27 WO claimed
US-20100113450-A1 Agent for Preventing and Alleviating Wrinkles SHISEIDO COMPANY LTD. (JP) 2010-05-06 US claimed
EP-2123253-A1 WRINKLING-PREVENTING AND -MODIFYING AGENT Shiseido Company, Ltd. (JP) 2009-11-25 EP claimed
US-20090136474-A1 Stabilized Protease Composition TROBIO AB (SE) 2009-05-28 US claimed
WO-2007035143-A1 STABILIZED PROTEASE COMPOSITION TROBIO AB (SE) 2007-03-29 WO claimed
EP-1637141-A1 Stabilized protease composition comprising a serine protease, morpholino derivatives and reversible inhibitors of said serine protease Trobio AB (SE) 2006-03-22 EP claimed
EP-0765160-B1 DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS UNIV RAMOT (IL) 2003-04-16 EP claimed
US-6096740-A BLOCK N-METHYL-ASPARTATE RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) 2000-08-01 US claimed
EP-0553174-B1 ARYLPYRIDAZINONES BYK GULDEN LOMBERG CHEM FAB (DE) 1998-07-08 EP claimed
EP-0765160-A4 1997-04-09 EP claimed
EP-0765160-A1 DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS RAMOT UNIVERSITY, AUTHORITY FOR APPLIED RESEARCH & INDUSTRIAL DEVELOPMENT LTD. (IL) 1997-04-02 EP claimed
WO-1995020958-A1 DEXANABINOL DERIVATIVES AND THEIR USE AS NEUROPROTECTIVE PHARMACEUTICAL COMPOSITIONS RAMOT UNIVERSITY AUTHORITY FOR APPLIED RESEARCH AND INDUSTRIAL DEVELOPMENT LTD. (IL) 1995-08-10 WO claimed
EP-0125636-B1 PYRIDAZINONES, THEIR PREPARATION AND USE, MEDICINES CONTAINING THESE PYRIDAZINONES Byk Gulden Lomberg Chemische Fabrik GmbH (DE) 1987-04-01 EP claimed
WO-1984004521-A1 PYRIDAZINONES, THEIR PREPARATION AND USE, AND MEDICAMENTS CONTAINING PYRIDAZINONES BYK GULDEN LOMBERG CHEM FAB (DE) 1984-11-22 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090136474-A1 Stabilized Protease Composition SERPINE1, SERPINB1, CTRL GLA 221/4885SMN1; SMN2 655/4885MAPK1 3866/4885
US-20100113450-A1 Agent for Preventing and Alleviating Wrinkles GABRB1, GABRB2, GABBR1 GLA 28/4885SMN1; SMN2 1147/4885MAPK1 2400/4885
US-20240002358-A1 Optically clear, taste-masked, shelf-stable nano-emulsions containing cannabinoids CNR2, CNR1, TAS2R10 GLA 1996/4885SMN1; SMN2 1534/4885MAPK1 4269/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.